Does E13.3491 require prior authorization?

No, E13.3491 does not require prior authorization (high confidence). Code is covered without prior authorization.

`E13.3491` — Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye

ICD-10-CM

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Medical record must document indication, route (intravitreal), dose and dosing frequency consistent with the FDA label or include literature support when dosing/frequency deviates from the FDA label.
The intravitreal administration must be billed with CPT 67028 on the same claim as the drug (or CPT 67027 for SUSVIMO) and must include the appropriate site modifier (RT, LT, or 50).
For Part A and Part B MAC claims, report the drug using the specified HCPCS/J-codes or Q-codes as listed by product (e.g., ranibizumab J2778/J2779 or Q5124/Q5128, aflibercept J0178 or J0177/Q-codes for biosimilars, brolucizumab-dbll J0179, faricimab-svoa J2777).
Medical records must document the clinical findings supporting the billed foot care service and be available upon request.

Intravitreal administration of ranibizumab (including ranibizumab-nuna and ranibizumab-eqrn), aflibercept (including aflibercept HD and biosimilars PAVBLU™, AHZANTIVE®, ENZEEVU™, OPUVIZ™, YESAFILI™), brolucizumab-dbll, and faricimab-svoa is covered when used consistent with the FDA-approved package insert or supported compendia/literature for off-label uses.
Foot care services are covered when the beneficiary has a listed systemic condition that justifies coverage per Medicare Benefit Policy Manual Pub.100-02, Ch.15, Section 290.4D.
For diagnosis codes designated by an asterisk, the patient must be under the active care of an M.D. or D.O., documented as having been seen for the complicating disease within the 6 months prior to service.
Claims asserting presumptive coverage must include a systemic-condition diagnosis from IOM 100-02 Ch.15 Section 290 Group 1 and a valid billing modifier Q7, Q8, or Q9.
Mycotic nail debridement is covered when mycotic nails are present in the context of a systemic disease with class findings and the appropriate Q modifier on the claim.
Mycotic nail debridement is covered without systemic disease if an ambulatory patient has marked limitation of ambulation, pain, or secondary infection from thickened/dystrophic infected toenail plate.

L38686 — Implantable Continuous Glucose Monitors (I-CGM)

J05

A57599 — Billing and Coding: Visual Electrophysiology Testing

J05

L37015 — Visual Electrophysiology Testing

J05

A56232 — Billing and Coding: Foot Care

J05

L34760 — Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)

Ask Verity about documentation requirements, denial risks, or coverage in your state.